Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Pralatrexate in Combination With Oxaliplatin in Advanced Esophago-gastric Cancer: A Phase II Trial With Predictive Molecular Correlates

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT01178944
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:36:43.683709+00:00
Published At
2017-12-13T00:00:00+00:00
Record Updated At
2017-12-13
Results Posted At
2017-12-13
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Adenocarcinoma of the Gastroesophageal Junction", "Esophageal Undifferentiated Carcinoma", "Gastric Adenocarcinoma", "Gastric Squamous Cell Carcinoma", "Recurrent Esophageal Adenocarcinoma", "Recurrent Esophageal Squamous Cell Carcinoma", "Recurrent Gastric Carcinoma", "Stage IIIB Esophageal Adenocarcinoma", "Stage IIIB Esophageal Squamous Cell Carcinoma", "Stage IIIB Gastric Cancer", "Stage IIIC Esophageal Adenocarcinoma", "Stage IIIC Esophageal Squamous Cell Carcinoma", "Stage IIIC Gastric Cancer", "Stage IV Esophageal Adenocarcinoma", "Stage IV Esophageal Squamous Cell Carcinoma", "Stage IV Gastric Cancer", "Undifferentiated Gastric Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2017-12-13"
protocolSection.identificationModule.nctId
"NCT01178944"
protocolSection.identificationModule.officialTitle
"Pralatrexate in Combination With Oxaliplatin in Advanced Esophago-gastric Cancer: A Phase II Trial With Predictive Molecular Correlates"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2017-12-13"

Study condition terms

  • Adenocarcinoma of the Gastroesophageal Junction (protocolSection.conditionsModule.conditions)
  • Esophageal Undifferentiated Carcinoma (protocolSection.conditionsModule.conditions)
  • Gastric Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Gastric Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Esophageal Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Esophageal Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Gastric Carcinoma (protocolSection.conditionsModule.conditions)
  • Stage IIIB Esophageal Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Stage IIIB Esophageal Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Stage IIIB Gastric Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIC Esophageal Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Stage IIIC Esophageal Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Stage IIIC Gastric Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Esophageal Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Stage IV Esophageal Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Stage IV Gastric Cancer (protocolSection.conditionsModule.conditions)
  • Undifferentiated Gastric Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.